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Endostatin, an inhibitor of angiogenesis, is a 20kDa fragment of the basement membrane protein, collagen XVIII. The formation of
endostatin relies upon the action of proteases on collagen XVIII. TNFa, produced by activated macrophages, is a multifunctional
proinflammatory cytokine with known effects on endothelial function. We postulated that TNFa may modulate the activities of
proteases and thus regulate endostatin formation in pancreatic cells. Collagen XVIII/endostatin mRNA was expressed in one
pancreatic cell line, SUIT-2, but not in BxPc-3. The 20kDa endostatin was found in the cell-conditioned medium of SUIT-2 cells.
Precursor forms only were found in the cells. Exogenous endostatin was degraded by cellular lysates of SUIT-2 cells. Elastase activity
was found in cell extracts but not the cell-conditioned media of SUIT-2 cells. Incubation of SUIT-2 cells with TNFa increased
intracellular elastase activity and also increased secretion of endostatin into the medium. We conclude that endostatin is released
by SUIT-2 cells and that increases in intracellular elastase, induced by TNFa, are correlated with increased secretion. Endostatin is
however susceptible to degradation by intracellular proteases and if tissue injury accompanies inflammation, endostatin may be
degraded, allowing angiogenesis to occur.
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Endostatin is a dose-dependent, specific inhibitor of endothelial cell
growth (O’Reilly et al, 1997). Recent in vitro studies using DNA and
antibody array have identified its antiangiogenic effects on
microvascular endothelial cells (Abdollahi et al, 2004). Systemic
administration of recombinant endostatin is capable of suppressing
the growth of metastases with no evidence of either toxicity in phase
I clinical trials or drug resistance (Folkman, 2004). Further clinical
trials using endostatin as an anticancer agent, are ongoing (Davis
et al, 2004). Endostatin is formed by the proteolytic degradation of
its parent molecule, collagen XVIII (Ferreras et al, 2000). Since
collagen XVIII is a component of the vascular basement membrane,
endostatin has been found in a large number of tissues. The
detection of a broad range of endostatin-like fragments in tissue
and serum with sizes ranging from 20 to 38kDa indicates that
collagen XVIII is sensitive to proteolytic degradation at a number of
sites. This suggests that a number of proteolytic pathways may exist
for the generation and degradation of endostatin.
The C terminus of collagen XVIII contains the NC1 domain
(38kDa) from which 20kDa endostatin is derived. Based on
structural data, Sasaki et al (2000) proposed that the NC1 segment
of collagen XVIII consisted of three different segments: an
association domain responsible for noncovalent trimerisation, a
hinge region susceptible to proteolytic degradation and the
compact endostatin domain. In vitro studies identified secreted
cathepsin L as an enzyme capable of generating endostatin,
whereas the matrix metalloproteases produce larger fragments in
an alternate pathway (Felbor et al, 2000). In vivo, proteolytic
processing of collagen XVIII can generate both the NC1 trimer
and the 20kDa endostatin monomer (Sasaki et al, 1998; Wen et al,
1999) since both fragments are found in tissues and serum
(Standker et al, 1997; John et al, 1999). In vitro, the NC1 fragment
is more sensitive to proteolytic degradation than 20kDa endostatin
(Ferreras et al, 2000).
We have previously identified endostatin in human pancreatic
cancer tissue and showed that it was susceptible to degradation by
elastase (Brammer et al, 2005). We sought to identify a pancreatic
cell line capable of endostatin production in order to examine
the regulation of endostatin production. We hypothesised that
endostatin production could be modulated by protease activity
under the influence of TNFa, a cytokine with multifunctional
effects in states of inflammation and malignancy.
There is much evidence to link proinflammatory cytokines with
malignancy in the pancreas as in other tissues (Farrow and Evers,
2002; Jura et al, 2005, Mantovani, 2005). Early studies showed that
TNFa produced by activated macrophages induced angiogenesis
(Leibovich et al, 1987), which would support carcinogenesis.
However, pancreatic ductal carcinoma is not a particularly
vascular malignancy, exhibiting instead a heterogeneous vascula-
rity with enhanced foci of endothelial proliferation (Korc, 2003).
This suggests that local factors control the angiogenesis. Further-
more, not all cases of pancreatitis lead to malignancy also
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ssuggesting that other factors are important. Pancreatic cancer cell
lines are known to produce many proteases and while some of
these will aid invasion of the metastatic cells, others may promote
endostatin production from collagen XVIII and thus limit tumour
spread. Our studies aim to understand how endostatin production
is regulated.
MATERIALS AND METHODS
Cell culture
SUIT-2 is a human pancreatic tumour cell line derived from a liver
metastasis and is known to display a highly metastatic phenotype
with spontaneous metastasis to lung and regional lymph nodes
from subcutaneous nude mouse xenografts (Taniguchi et al, 1992).
BxPc-3 were derived from an adenocarcinoma of the body of the
pancreas and are moderately differentiated (Tan et al, 1986). Cells
were cultured in Rivers Park Memorial Institute (RPMI) 1640
media supplemented with 10% foetal bovine serum and grown
in an incubator at 371C, in an atmosphere of 5% CO2 and 95%
humidified air. Cell culture medium was supplemented with
penicillin (10
5IUl
 1) and streptomycin (100mgl
 1). Cells were
tested and were negative for mycoplasma.
Reverse transcriptase–polymerase chain reaction
(RT–PCR)
Reverse transcriptase–polymerase chain reaction was used to
determine whether cells expressed mRNA for collagen XVIII-
endostatin. Total RNA was isolated from SUIT-2 cells, BxPc-3 cells
and two samples of normal pancreatic tissue using Trizol (Gibco-
BRL, Paisley, UK) as described by the manufacturer. The RNA was
dissolved in RNAase-free, diethyl pyrocarbonate-treated water and
stored at  701C until use.
Primers were designed using Primer 3 software (http://www.
genome.wi.mit.edu/cgi-bin/primer/primer3-www.cgi) from the
sequences for endostatin listed on GeneBank. The primers were
ENDO SENSE CTCAATGCAGAGCACGATGT
ENDO ANTISENSE
TGTTCTCAGGCTCTGAGGGT
The RT–PCR reaction was performed using Ready-To-Go
RT–PCR beads (Amersham Biosciences, UK) according to the
manufacturer’s instructions. After the RT reaction for 30min at
421C, the samples were heated to 941C for 5min, then through 35
cycles of 951C for 1min, 551C 1min and 721C for 2min. The
expected product size was 269bp.
The samples were run at 50V on 1% agarose gels for 2–3h in
Tris-borate-EDTA buffer and ethidium bromide-labelled bands
visualised on the gel under an ultraviolet lamp. Known molecular
weight standards were run concomitantly to allow sizing of the
products.
Western blotting
Western immunoblotting, which separates immunoreactive frag-
ments of collagen XVIII by molecular weight was employed to
detect endostatin (20kDa). SUIT-2 cells were cultured until
subconfluent and then cultured for 2 or 3 days in serum-free
media. Secreted proteins were collected by precipitation from three
volumes of ethanol and dissolved in reducing sample buffer (2%
sodium dodecyl sulphate (SDS), 62.5mM Tris-HCl, 10% glycerol,
10% 2-mercaptoethanol, pH 6.8) for SDS-polyacrylamide gel
electrophoresis (SDS–PAGE). The cell layer proteins were also
analysed by SDS–PAGE to allow comparison between secreted and
nonsecreted endostatin-related fragments. Detection was as
described previously (Brammer et al, 2005) using enhanced
chemiluminescence with rabbit polyclonal antisera to human
endostatin (Chemicon, Hampshire, UK) diluted 1:100. The
specificity of the antisera was shown by preabsorption of the
antibody with an excess of recombinant endostatin. Preabsorbed
antisera did not bind to any proteins on Western blots of
pancreatic tissue, whereas the nontreated antisera reacted with
discrete proteins of various sizes including that of full-length
collagen XVIII.
Subcellular fractionation of SUIT-2 cells
SUIT-2 cells were scraped from dishes and suspended in 1ml of
HBSS. The cells were sonicated in an ice bath to avoid heating
during disruption. The suspension was centrifuged at 3000g for
30min and the supernatant was diluted to a protein concentration
of 1mgml
 1 with HBSS pH 7.2. Five nanograms of recombinant
endostatin was incubated with 150ml of SUIT-2 cell lysate
(1mgml
 1 protein) and incubation at 371C was terminated at
various time points by freezing at  201C. A volume of 50mlo f5 
reducing sample buffer was added to the samples which were
heated at 1001C for 10min before separation by SDS–PAGE.
Elastase activity in SUIT-2 cells
Activity of elastase in the pancreatic cell line was evaluated using a
colorimetric assay with N-methoxysuccinyl-Ala–Ala–Pro–Val P-
nitroanilide as a chromogenic substrate as described by Bieth and
Wermuth (1973). A total of 10 million SUIT-2 cells were suspended
in 0.5ml of 20mM HEPES buffer, 0.25 M sucrose pH 7.2, and
sonicated in an ice bath to avoid heating during cell disruption.
Five 30s pulses were used. The suspension was centrifuged at
1000g for 10min and the supernatant was centrifuged again at
2000g for 30min. The supernatant was diluted to a protein
concentration of 1mgml
 1 with 20mM HEPES, 0.25 M sucrose, pH
7.2.
The enzyme kinetics of the pancreatic cellular extract were
evaluated and the sensitivity of the assay was verified using
purified elastase (Sigma, UK). Incubation was performed at room
temperature and the plate was read at intervals between 5 and
30min up to a period of 24h. The results were analysed by plotting
a Lineweaver–Burk curve to determine the Km and Vmax.
Effect of TNFa on endostatin production and degradation
The effect of the cytokine TNFa was investigated to determine
whether endostatin production from collagen XVIII could be
modulated by cytokines. Secretion of endostatin into the media
was examined. The effect of cell extracts on endostatin degradation
was determined as described in the previous section.
SUIT-2 cells were cultured for 48h in serum-free RPMI media
in 9.6cm
2 culture plates in the presence of TNFa. After removal
from the cells, 1ml of the cell-conditioned medium was incubated
with 5ng of recombinant endostatin at 371C for 4h to determine
whether degradation of the exogenous endostatin occurred as a
result of proteases released into the media. The secreted proteins
were concentrated from the cell-conditioned culture medium by
ethanol precipitation and analysed by SDS–PAGE and immuno-
blotting.
RESULTS
RT–PCR for collagen XVIII/endostatin
A single band of approximately 269bp corresponding to the
expected product size was seen with two samples of normal
pancreatic tissue and the pancreatic cell line, SUIT-2 as shown in
Figure 1. BxPc-3 cells did not express mRNA for collagen XVIII
and were not used further.
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line
Western blotting, shown in Figure 2, demonstrated that not only
collagen XVIII but also 20kDa endostatin are produced by SUIT-2
cells. Endostatin is secreted into the cultured cell media but not
found in the cell layer. The higher molecular weight forms of
endostatin-related proteins were found in both the cell layer and
the cell-conditioned media and were of similar size, the
predominant products being 36–38kDa which is likely to be the
NC1 domain, and 70kDa.
Endostatin degradation by SUIT-2 cellular lysate
The time course of degradation of exogenous endostatin by lysates
of SUIT-2 cells is shown in Figure 3. Visible evidence of endostatin
degradation was seen by 150min. By 22h none remained. The
band at 70kDa became more prominent with incubation and this
corresponded to a reduction in the 120kDa band. Interestingly,
the 36kDa endostatin-related fragment was very susceptible to
degradation. The difference between the CL and the t¼0 is that
the CL sample was immediately dissolved in reducing sample
buffer whereas the t¼0 extract had been sonicated and
centrifuged. There is complete loss of the 36kDa band during
the homogenisation period.
Elastase activity in SUIT-2 cells
Elastase activity, measured by the colorimetric method, in the cell
extracts and in 48h collection of serum-free cell conditioned
medium is shown in Figure 4. There was detectable elastase in the
cell layer yet there was none in the 48h cell-conditioned medium.
From the Lineweaver–Burk curve shown in Figure 5, we were
able to calculate the Vmax and Km for the reaction as 16mMs
 1
and 0.2mM, respectively. This compares with the Km of 1.1mM for
an elastase we identified in human pancreas (Brammer et al, 2005)
and human leukocyte elastase where the Km is reported to be
0.14mM (Castillo et al, 1979).
S B P1 P2 O M
kB
Figure 1 RT–PCR showing collagen XVIII-endostatin mRNA expression
in pancreatic tissue and pancreatic cancer cell lines. S¼Suit-2, B¼BxPc3,
P1&P2¼normal pancreas, O¼water control.
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- 120
- 70
- 36
- 20
kDa
CL
Figure 2 Western immunoblotting of SUIT-2 cell layer and cell-
conditioned media probed for endostatin (CM¼cell media; CL¼cell
layer).
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- 36
- 20
- 70
- 120
kDa
0 45 90 120 150 180 22  h
Figure 3 Western immunoblotting showing degradation of recombinant
endostatin with time by SUIT-2 cellular lysates probed for endostatin.
(CL¼cell layer without homogenisation).
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Figure 6 shows the effect of incubation of SUIT-2 cells with TNFa
for 48h on endostatin secretion. The 20kDa endostatin in the cell-
conditioned medium was increased in a dose-dependent manner
following 48h treatment with TNFa. The intensity of the other
endostatin-related fragments was unchanged.
Effect of TNFa on endostatin degradation and elastase
activity
Figure 7 shows the effects of incubating exogenous endostatin with
the cell-conditioned medium from the experiment described in
Figure 6. Although there was appreciable degradation of exo-
genous endostatin following the 4h incubation, there were no
convincing changes with increasing dose of TNFa.
Effect of TNFa on elastase activity
Figure 8 shows the effect of TNFa on intracellular elastase activity,
measured using the colorimetric assay. The results are shown as
percentage change from control. Incubation with TNFa increased
intracellular elastase activity in a dose-dependent manner in the
SUIT-2 cell layer.
DISCUSSION
We have shown that the SUIT-2 cells, but not BxPc-3 cells, express
the mRNA for collagen XVIII. Western immunoblotting confirmed
that these cells can produce mature 20kDa endostatin from
collagen XVIII and therefore possess the necessary proteolytic
enzymes required for synthesis. Mature endostatin was found in
the cell-conditioned media where higher molecular weight forms
of endostatin-related proteins were also found. This suggests that
collagen XVIII, which is normally considered as an integral
membrane protein, can be readily released into medium. Whether
this is due to enzymatic action is not clear. The 20kDa form of
endostatin was not present in the cell layer, however collagen
XVIII and several immunoreactive precursors of endostatin were
present. The absence of the 20kDa endostatin within the cells
implies that either intracellular endostatin is degraded or that
endostatin is processed at the cell membrane from the larger
fragments of collagen XVIII and secreted.
We found that extracts of SUIT-2 cells were capable of degrading
endostatin and endostatin-related fragments of collagen XVIII.
The 36kDa endostatin-related fragment was particularly susceptible
to proteolysis, once the subcellular organisation of cells was
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Figure 4 Rate of hydrolysis of the elastase substrate by SUIT-2 cell
extract and serum-free cell-conditioned culture media.
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Figure 5 A Lineweaver–Burk plot for assay of intracellular SUIT-2
elastase activity.
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Figure 6 Western immunoblotting showing dose-dependent effects of
TNFa on secretion of endostatin and endostatin-related proteins into
culture media by SUIT-2 cells treated with varying doses of TNFa for 48h.
0
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Figure 7 Western immunoblotting showing effect of incubating
exogenous endostatin with cell-conditioned media from cells treated with
varying doses of TNF for 48h. 0 and 4h incubation times are shown.
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Figure 8 Dose-dependent effect of TNFa upon intracellular elastase
activity in the SUIT-2 cell layer shown as percentage change in activity.
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fragment may undergo proteolysis to a variable extent by a
number of proteases such as cathepsins D and L which are
lysosomal enzymes, matrix metalloproteases and elastase.
Cathepsins are produced by both endothelial cells and tumour
cells and these proteases are activated by the acidic pH that is
found in the surroundings of tumours. Although they may have a
role in endostatin generation (Felbor et al, 2000), they may also be
important in endostatin degradation. We previously implicated
elastase in the degradation of endostatin in extracts of normal
pancreas (Brammer et al, 2005). The release of intracellular
proteases that degrade endostatin following tissue injury, may be a
means to reduce local endostatin levels. This would allow
angiogenesis to occur and thus initiate healing but may also aid
in tumour establishment.
TNFa increased the secretion of endostatin in a dose-dependent
manner but did not alter the release of intermediate endostatin-
related fragments of collagen XVIII. TNFa treatment may therefore
act by increasing the activity of an intracellular protease producing
endostatin from collagen XVIII. TNFa increased intracellular
elastase activity which was correlated with increased levels of
secreted endostatin. We did not find secreted elastase activity but
we did show that exogenous endostatin was lost from the medium.
Either there is secretion of proteases, which presumably are not
elastases, which degrade endostatin or endostatin is taken up and
degraded by the intracellular proteases.
We characterised the intracellular elastase expressed in SUIT-2
cells. We found that the Km for this enzyme differed from that
of the human pancreatic elastase we had previously characterised
and from human leucocyte elastase. Yamaguchi et al (2000) also
described a novel elastase in these cells, distinct from human
leucocyte elastase, which had similar activity to neutrophil elastase
but was immunologically different. Furthermore, this novel
elastase was not inhibited by neutrophil elastase and pancreatic
elastase inhibitors.
We conclude that SUIT-2 cells can synthesise and secrete
endostatin and that this synthesis can be increased by TNFa.
Endostatin would oppose the known effects of TNFa to increase
angiogenesis by increasing the secretion of vascular endothelial
growth factors (VEGF) (Farrow and Evers, 2002; Korc, 2003).
Clinically, increased production of endostatin from normal
pancreatic cells due to TNFa production from macrophages would
limit healing of the inflamed pancreas. Where the balance lies in
these antagonistic effects is likely to vary and may explain the
heterogeneous angiogenesis seen in pancreatic disease.
If endostatin production were increased, and angiogenesis
therefore limited, this would result in hypoxia. Hypoxia increases
the expression of VEGF by the cells which stimulates angiogenesis
(Farrow and Evers, 2002; Korc, 2003; Jura et al, 2005). Hypoxia
however induces many other changes in the proteome which
promote cell survival, proliferation and spread. Cells adapt to
changes in nutrient availability by changes the expression of
glucose transporters and glycolytic enzymes (Vaupel and Harrison,
2004). These changes may promote the selection of tumour cells
that are able to survive adverse conditions. This hypothesis could
explain clonal selection of malignant cells from inflamed
pancreatic tissue that are more aggressive and capable of
metastasising.
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